Classification of statins/dosages according to the attainable

Slides:

Advertisements

Similar presentations

Time line of data collection in the Nurses’ Health Study, 1988 to 2000 A. Heather Eliassen et al, Arch Intern Med. 2005; 165:

Advertisements

Flow chart showing number of citations retrieved by individual searches and number of trials included in review Strippoli GF, et al. BMJ 2008 Feb 25 [Epub.

Nonsense Mutations in PCSK9 and Cardiovascular Risk Factors among 3363 Black Participants in the Study Jonathan C.Cohen, et al, N Engl J Med 2006;354:

Weng TC, et al. J Clin Pharm Ther 2010;35:

* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.

Kotseva K, et al. Eur J Cardiovasc Prev Rehabil 2009 Mar 12 [Epub]

Glynn RJ, et al. N Engl J Med 2009 Mar 29 [Epub ahead of print]

Characteristics of new users of statins in the period 1991–2004 in the PHARMO population F.J.A. Penning-van Beest, et al. European Heart Journal 2007;28:154–159.

The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT Systolic Heart failure.

A Global Perspective on Blood Pressure Treatment and Control in a Referred Cohort of Hypertensive Patients Bramlage P, et al. J Clin Hyper. doi: /j x.

Age-standardized mortality from ischaemic heart disease in European regions (men; age group years; year 2000) J Muller-Nordhorn, et al. Eur Heart.

Trial profile Prakash Deedwania, et al. Lancet 2006; 368:

Multivariate associations* between selected covariates and statin use Jawahar L. Mehta, et al. Am J Cardiol 2006;98:923–928.

Definition of measurements and patients Michael J. Murphy, et al. Br J Clin Pharmacol 2008;65:

Trial profile SAS denotes the Simvastatin in Aortic Stenosis Study

Drugs for Lipid Disorders

Copyright © 2017 American Academy of Pediatrics.

Statin Myopathy (AHA/ACC/NHLBI)

Copyright © 2012 American Medical Association. All rights reserved.

Scandinavian Simvastatin Survival Study (4S)

Prehypertension, Diabetes, and Cardiovascular Disease Risk in a Population-Based Sample by Ying Zhang, Elisa T. Lee, Richard B. Devereux, Jeunliang Yeh,

Behavior and Biology: The Basic Sciences for AHA Action

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

Charles R. Harper, MD, Terry A. Jacobson, MD Mayo Clinic Proceedings

2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis? Sripal Bangalore, MD,

Neil J. Stone et al. JACC 2014;63:

Sunjoo Boo, RN, PhD, Erika Sivarajan Froelicher, RN, PhD, FAAN

Systolic Heart failure treatment with the If inhibitor ivabradine Trial The effect of heart rate reduction with ivabradine on renal function in patients.

Martin W. Schoen, MD, MPH, Joanne Salas, MPH, Jeffrey F

Figure 3 Global rates of sodium, fruit, and vegetable intake

Figure 4 Precision prescribing

Charles R. Harper, MD, Terry A. Jacobson, MD Mayo Clinic Proceedings

VALUE Trial design: Hypertensive patients at high cardiovascular risk were randomized to valsartan (n = 7,649) vs. amlodipine (n = 7,596). Results (p =

A PCP's Guide to Dyslipidemia

Distribution of lifespan for men initiating preventative therapy (with a risk reduction of 30%) at the age of 50, with national average blood pressure.

Fellström BC, et al. N Engl J Med 2009;360:1455-7

How to Teach it?.

Selmer R, et al. Br J Clin Pharmacol 2009;67:355-62

Description of studies for pooled analyses

Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National.

Level of risk factor control in the overall sample and by gender

Relative risk reduction for incident hypertension associated with weight loss of 6.8 kg: The Framingham Study Cohort Risk reduction (%) Relative risk.

NAFLD (nonalcoholic fatty liver disease), CVD, and type 2 diabetes: Details of the study design Targher G et al. Diabetes Care 2007;30:

Khurram Nasir et al. JACC 2015;66:

Potential mechanisms whereby statins may reduce the risk of stroke

Recommendations for the management of patients with homozygous familial hypercholesterolaemia: Overview of a new European Atherosclerosis Society consensus.

Relative risks of clinical events for primary and secondary prevention with selected drugs Thomas A Gaziano, et al. Lancet 2006; 368:

Baseline Characteristics, Values at 24-Month Follow-up, and Changes from Baseline* - Part I John J.P. Kastelein, et al. N Engl J Med 2007;356: online.

Intensity of statin treatment and possible lipid lowering treatment intolerance and/or ineffectiveness issues among patients with type 2 diabetes (aged.

Temporal changes in population rates of cardiac services, demographics, and AMI prevalence (relative to 1992) David A. Alter, et al, Circulation 2006;113;

Perreault S, et al. Eur J Clin Pharmacol 2009 Jun 16 [Epub]

Rhanderson Cardoso, MD, Roger S

Characteristics of Large Randomized Controlled Statin Trials Included in the Present Analysis Alawi A. et al. JACC 2008 Aug 20 [Epub ahead of print]

Relative Risk of Onset of Cancer from the Cholesterol Treatment Trialists’ (CTT) Meta-Analysis of Statin Trials, According to Year of Onset Risk ratios.

Clinical Characteristics, Biochemical and Lipid Profiles, and Carotid IMT in 196 Asymptomatic Subjects With Familial Hypercholesterolemia Mireia Junyent,

Receiver operating curves (ROC) of simple age and gender adjusted risk factor models for predicting 10-year risk of cardiovascular disease comparing the.

Titration activities from baseline up to 6 and 12 months follow-up in nurse-coordinated care (NCC) versus usual care patients. X-as: patients (percentage),

Change in markers of glycometabolism and cardiovascular risk profile.

Percentage of patients with type 2 diabetes with A1C < 7% (n = 248), blood pressure > 130/80 mmHg (n = 248), and LDL cholesterol < 100 mg/dl (n = 207)

Morbidity and mortality benefits with statin use in observational studies on a logarithmic scale. Morbidity and mortality benefits with statin use in observational.

Amir A. Mahabadi et al. JIMG 2017;10:

Distribution of patients in the first- or second-year follow-up according to the number of acute exacerbations of chronic obstructive pulmonary disease.

ORs of receiving metformin for outcome measures, including age, number of comorbidities, provider age, A1C level, history of CHF, and use of medications,

J. David Spence, BA, MBA, MD Canadian Journal of Cardiology

LDL-c reductions below 1

Differences in changes in total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides (expressed as mg/dL) between patients with hyperlipidaemia.

Baseline characteristics of people who inject drugs enrolled in the Montreal Hepatitis C Cohort (2004–2017), by prescribed dosage of opioid agonist treatment,

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

Forest plot showing survival c-statistics for selected models, applied to the testing cohort. Forest plot showing survival c-statistics for selected models,

Receiver operating characteristic curve showing results for two selected models, applied to the testing cohort. Receiver operating characteristic curve.

Presentation transcript:

Classification of statins/dosages according to the attainable reduction of cholesterol-low-density lipoprotein (c-LDL) level Poluzzi E, et al. Eur J Clin Pharmacol 2008 [Epub ahead of print]

Use of statins in the Emilia Romagna region of Italy, in Italy and in the cohort of the present study Poluzzi E, et al. Eur J Clin Pharmacol 2008 [Epub ahead of print]

Distribution of patients by choice of statin, tablet dosage and number of tablets received in the year Poluzzi E, et al. Eur J Clin Pharmacol 2008 [Epub ahead of print] Note: The figure on lovastatin is not shown due to the low prevalence of use of the drug (only 68 patients were prescribed lovastatin)

Patients’ characteristics Poluzzi E, et al. Eur J Clin Pharmacol 2008 [Epub ahead of print]

Distribution of patients according to cardiovascular risk profile and coverage Poluzzi E, et al. Eur J Clin Pharmacol 2008 [Epub ahead of print]

Analysis of statin coverage according to age, gender, therapeutic regimen and patient’s risk factors Poluzzi E, et al. Eur J Clin Pharmacol 2008 [Epub ahead of print]